Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
07 janv. 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael”), a leader in the field of cancer metabolism, today announced that Sanjeev Luther, President & CEO of Rafael...
Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
11 déc. 2018 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a phase...
Newly Published Data from National Study Supports Interpace Diagnostics’ PancraGEN®
26 nov. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
New Article in Peer-Reviewed Journal Highlights Important Role of PancraGEN® Testing PARSIPPANY, NJ, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
New Pancreatic Ductal Adenocarcinoma Research Published in Journal of Visualized Experiments
15 nov. 2018 08h00 HE
|
Crown Bioscience
Paper describes well-established protocols for PDAC orthotopic tumor homograft model development and immunoprofiling SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug...
Interpace Diagnostics Announces New Coverage by Blue Cross Blue Shield for Thyroid Testing
07 nov. 2018 08h06 HE
|
Interpace Diagnostics Group, Inc.
The Federal Employee Health Benefit BCBS Program Adds Approximately 5.3 Million Covered Lives PARSIPPANY, NJ, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
06 nov. 2018 08h01 HE
|
Sorrento Therapeutics, Inc.
Two out of four patients showed complete resolution of liver metastases on PET scanMedian overall survival (OS) 8.3 months and mean OS 9.8 months, compared to the standard of care 3 to 6 monthsMeeting...
PanTher Therapeutics Announces Agreement with MD Anderson Cancer Center and Appointment of Senior Clinical Advisor
16 oct. 2018 12h05 HE
|
PanTher Therapeutics
CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE NEWSWIRE) -- PanTher Therapeutics, the biotech company developing drug-delivery platforms for unresectable, locally advanced solid tumors, today announced an...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
15 oct. 2018 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals, Inc. will be presenting at the BIO Investor Forum 2018 in San Francisco...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
09 oct. 2018 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, its President...
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...